Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 5/20 | 0.39 |
| ▸ | BCL2L2 | Q92843 | 5/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597189 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2MMETSHRBCL2BCL2L2 | |
| SCHEMBL4597482 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2MMETSHRBCL2BCL2L2 | |
| SCHEMBL15623808 | 0.79 | ALDH1A1 (0.53) | SMN1; SMN2MMEBCL2BCL2L2MCL1 | |
| SCHEMBL5705701 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2MMEBCL2BCL2L2MCL1 | |
| SCHEMBL542270 | 0.76 | ALDH1A1 (0.50) | SMN1; SMN2MMEBCL2BCL2L2MCL1 | |
| SCHEMBL4597621 | 0.75 | TSHR (0.39) | MMETSHRALDH1A1PKMMEN1 | |
| SCHEMBL4595958 | 0.75 | TSHR (0.39) | MMETSHRALDH1A1PKMMEN1 | |
| SCHEMBL4595954 | 0.75 | TSHR (0.39) | MMETSHRALDH1A1PKMMEN1 | |
| SCHEMBL5778952 | 0.74 | TSHR (0.39) | MMETSHRBCL2MCL1ALDH1A1 | |
| SCHEMBL29901248 | 0.73 | SMN1; SMN2 (0.48) | SMN1; SMN2MMEBCL2BCL2L2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506177-B1 | PROCESS FOR THE PREPARATION OF THE ENANTIOMERIC FORMS OF 2-SUBSTITUTED 2-(2,5-DIOXOIMIDAZOLIDIN-1-YL)-ACETIC ACID DERIVATIVES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-01-16 | — | — | EP | disclosed |
| US-6908752-B2 | Process for the preparation of the enant iomeric forms of 2-substituted 2- (2, 5-dioxoimidazolidin-1yl) -acetic acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-21 | — | — | US | disclosed |
| EP-1506177-A2 | PROCESS FOR THE PREPARATION OF THE ENANTIOMERIC FORMS OF 2-SUBSTITUTED 2-(2,5-DIOXOIMIDAZOLIDIN-1-YL)-ACETIC ACID DERIVATIVES | Aventis Pharma Deutschland GmbH (DE) | 2005-02-16 | — | — | EP | disclosed |
| US-20030054507-A1 | Process for the preparation of the enant iomeric forms of 2-substituted 2- (2, 5-dioxoimidazolidin-1-yl) -acetic acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2003008386-A2 | PROCESS FOR THE PREPARATION OF THE ENANTIOMERIC FORMS OF 2-SUBSTITUTED 2-(2,5-DIOXOIMIDAZOLIDIN-1-YL)-ACETIC ACID DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | WO | disclosed |